Cardiometabolic Comorbidities in COPD: Focus on Diabetes, GLP-1 Receptor Agonists, SGLT-2 Inhibitors and Antidiabetic Drugs - PubMed
4 hours ago
- #COPD
- #Antidiabetic Therapies
- #Type 2 Diabetes
- COPD and type 2 diabetes (T2D) share overlapping mechanisms like systemic inflammation, oxidative stress, hypoxia, and metabolic dysregulation.
- Patients with both COPD and T2D face higher risks of exacerbations, hospitalizations, cardiovascular events, and reduced quality of life.
- Lifestyle interventions such as smoking cessation and structured physical activity are foundational for managing COPD and T2D.
- Antidiabetic therapies like GLP-1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors (SGLT-2is) may offer pulmonary, metabolic, and cardiovascular benefits.
- These therapies modulate inflammation, oxidative stress, endothelial function, and insulin sensitivity, potentially reducing COPD exacerbations and improving lung function.
- Safety concerns include glucocorticoid-induced hyperglycemia and hypoxia-related metabolic complications, requiring careful monitoring.
- Optimal care involves a multidisciplinary approach integrating pulmonology, endocrinology, primary care, nutrition, and rehabilitation.
- Large randomized controlled trials and standardized definitions are needed to guide personalized therapeutic strategies.